LPCN Lipocine Inc.
Lipocine Inc. (LPCN) is expected to report earnings on November 3, 2026, before the market open. The consensus earnings estimate is a loss of $0.47 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.9% since its last earnings release on August 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Lipocine Inc.
Lipocine Inc is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health.
Sector
Healthcare
Industry
Drug Manufacturers/Other